LIST OF TABLES
1-1.
Physical and chemical properties of barium and selected barium compounds . . . . . . . . . 5
4-1.
Incidence and mean severity scores for nephropathic lesions in B6C3F1
mice exposed to barium chloride dihydrate in drinking water . . . . . . . . . . . . . . . . . . . . 19
5-1.
Effects of subchronic and chronic oral barium exposure on rodents . . . . . . . . . . . . . . . . 44
5-2.
Nephropathy in B6C3F1 mice chronically exposed to barium in drinking water . . . . . . 45
5-3.
Comparison of best fitting models fits and benchmark doses for increased risk of
nephropathy in mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
LIST OF FIGURES
B-1.
Third degree multistage for increased incidence of nephropathy in male mice . . . . . . B-2
B-2.
Output for multistage model for increased incidence of nephropathy in male mice . . . B-3
v
FOREWORD
The purpose of this Toxicological Review is to provide scientific support and rationale
for the hazard and dose-response assessment in IRIS pertaining to chronic exposure to barium
and soluble compounds. It is not intended to be a comprehensive treatise on the chemical or
toxicological nature of barium.
In Section 6, Major Conclusions in the Characterization of Hazard and Dose Response,
EPA has characterized its overall confidence in the quantitative and qualitative aspects of hazard
and dose response by addressing knowledge gaps, uncertainties, quality of data, and scientific
controversies. The discussion is intended to convey the limitations of the assessment and to aid
and guide the risk assessor in the ensuing steps of the risk assessment process.
For other general information about this review or other questions relating to IRIS, the
reader is referred to EPA’s Risk Information Hotline at 202-566-1676.
vi
AUTHORS, CONTRIBUTORS, AND REVIEWERS
CHEMICAL MANAGERS/AUTHORS
1
Stiven Foster, M.S. (2005)
National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Washington, DC
Harlal Choudhury, D.V.M., Ph.D., D.A.B.T. (1998)
National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Cincinnati, OH
CONTRIBUTING AUTHORS
Joan Colman, Ph.D. (1998)
Senior Scientist
Syracuse Research Corporation
Syracuse, NY
Lisa Ingerman, Ph.D. (1998)
Senior Scientist
Syracuse Research Corporation
Portland, OR
Phillip Robbins, M.S. (1998)
Scientist
Syracuse Research Corporation
Cincinnati, OH
REVIEWERS
This document and the accompanying IRIS Summary have been peer reviewed by EPA
scientists and independent scientists external to EPA. Comments from all peer reviewers were
evaluated carefully and considered by the Agency during the finalization of this assessment.
During the finalization process, the IRIS Program Director achieved common understanding of
the assessment among the Office of Research and Development; Office of Air and Radiation;
Office of Prevention, Pesticides, and Toxic Substances; Office of Solid Waste and Emergency
Response; Office of Water; Office of Policy, Economics, and Innovation; Office of Children’s
Health Protection; Office of Environmental Information; and EPA’s regional offices.
1
Dates pertain to the version of the IRIS assessment. The oral reference dose added to
IRIS in 1998 was revised in 2005.
vii
AUTHORS, CONTRIBUTORS, AND REVIEWERS (continued)
INTERNAL EPA REVIEWERS
Harlal Choudhury, D.V.M., Ph.D., D.A.B.T. (2005)
National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Cincinnati, OH
Lynn Flowers, Ph.D., D.A.B.T. (2005)
National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Washington, DC
Edward Ohanian, Ph.D. (1998)
Senior Health Scientist
Health and Ecological Criteria Division
Office of Water
U.S. Environmental Protection Agency
Washington, DC
Vanessa Vu, Ph.D. (1998)
Director, Risk Assessment Division
Office of Prevention, Pesticides, and Toxic Substances
U.S. Environmental Protection Agency
Washington, DC
EXTERNAL PEER REVIEWERS
Eliseo Guallar, M.D., Dr. Ph. (2005)
Johns Hopkins Medical Institutions
Baltimore, MD
Y. James Kang, D.V.M., Ph.D. (2005)
University of Louisville
Louisville, KY
Lawrence Lash, Ph.D. (2005)
Wayne State University
Detroit, MI
viii
AUTHORS, CONTRIBUTORS, AND REVIEWERS (continued)
Paul Mushak, Ph.D. (1998 and 2005)
PB Associates
Durham, NC
Robert G. Tardiff, Ph.D., ATS (2005)
The Sapphire Group, Inc.
Washington, DC
Marvin Goldman, Ph.D. (1998)
University of California, Davis
Davis, CA
Arthur Gregory, Ph.D., D.A.B.T. (1998)
Techto Enterprises
Luray, VA
Summaries of the external peer reviewers’ comments and public comments and the
dispositions of their recommendations are in Appendices A-1 and A-2.
ix
Dostları ilə paylaş: |